Clindamycin 2% | Tacrolimus 0.09% | Niacinamide 3%

Route: Topical application to affected facial or body skin as directed.

• Apply a thin, even layer once or twice daily to affected areas and gently rub in.
• Avoid eyes, lips, mucous membranes, and open wounds.
• Do not use under occlusive dressings (tacrolimus systemic absorption risk).
• Use broad-spectrum SPF 30+ sunscreen on treated areas; tacrolimus may increase photosensitivity.

Dosing frequency and duration are prescriber-determined based on condition severity and patient response:

• Typically applied once to twice daily to affected areas.
• Tacrolimus-containing preparations are generally used for the minimum duration necessary to achieve control.
• Clinical reassessment at 4–6 weeks is recommended; long-term intermittent use may be appropriate for chronic conditions (e.g., rosacea).
• Final dosing decisions are made by the prescribing clinician.

• Clindamycin (2%): Bacteriostatic agent; binds 50S ribosomal subunit in gram-positive anaerobes, blocking peptide chain elongation. Reduces C. acnes density in hair follicles, lowering the production of inflammatory lipases and free fatty acids that drive follicular inflammation.
• Tacrolimus: Binds cytosolic FKBP-12; the complex competitively inhibits calcineurin phosphatase, preventing dephosphorylation of cytoplasmic NFAT (nuclear factor of activated T cells). NFAT cannot translocate to the nucleus to drive transcription of IL-2, IL-4, IL-5, IFN-γ, and TNF-α. Also inhibits mast cell degranulation and may suppress neuropeptide-mediated vascular responses relevant to rosacea pathophysiology.
• Niacinamide: Anti-inflammatory via NF-κB suppression in keratinocytes; stimulates de novo ceramide, cholesterol, and free fatty acid synthesis in the stratum corneum, improving barrier integrity; inhibits melanosome transfer; inhibits poly(ADP-ribose) polymerase-1 (PARP-1), reducing DNA damage-induced inflammatory signaling.

Indicated for inflammatory facial dermatoses combining acne and a rosacea or eczematous inflammatory component, where topical corticosteroids are undesirable. Tacrolimus is often chosen for patients with a history of steroid-induced adverse effects (atrophy, rosacea) on the face.

Prescriber monitoring:

• Tacrolimus Boxed Warning: Rare cases of lymphoma and cutaneous malignancy reported with prolonged topical calcineurin inhibitor use; use minimum necessary duration; avoid in immunocompromised patients.
• Monitor for viral superinfection (HSV, VZV) at treated sites.
• Antibiotic resistance surveillance with ongoing clindamycin use.
• Evaluate for bacterial, fungal, or viral infections at application sites before each renewal.

Contraindications:

• Hypersensitivity to clindamycin, lincomycin, tacrolimus, or niacinamide
• Netherton syndrome or generalized skin barrier defects (risk of high tacrolimus systemic absorption)
• Active cutaneous infections at application site
• Active malignancy at application site

Warnings & Precautions:

• Tacrolimus Boxed Warning: Long-term safety not fully established; avoid prolonged continuous use; not a first-line agent for minor conditions where alternative therapies exist.
• Photosensitivity on treated skin; require sun avoidance and sunscreen use.
• Risk of herpes simplex or varicella zoster reactivation at treated areas.
• Topical clindamycin: rare cases of antibiotic-associated pseudomembranous colitis (systemic absorption); discontinue and investigate if persistent diarrhea occurs.

Drug Interactions:

• CYP3A4 inhibitors (ketoconazole, fluconazole, erythromycin) may increase tacrolimus systemic exposure with extensive body-surface application; generally low clinical significance for small-area facial use.
• Erythromycin: antagonistic to clindamycin antibacterial activity in vitro.

Common Side Effects: Application site burning and pruritus (especially with tacrolimus, in first 1–2 weeks); skin dryness; niacinamide is well-tolerated; rare—herpes simplex reactivation.

Store at controlled room temperature (20–25°C / 68–77°F). Protect from light and heat. Do not freeze. Keep tightly sealed. Use before the beyond-use date assigned by Genesis Compounding. Keep out of reach of children.

Why is tacrolimus used instead of a corticosteroid for facial inflammation?

Topical corticosteroids used on the face long-term can cause skin atrophy, telangiectasias, and steroid-induced rosacea. Tacrolimus suppresses inflammation via a calcineurin inhibition mechanism and does not thin the skin, making it preferable for chronic facial inflammatory conditions requiring prolonged anti-inflammatory therapy.

What is the Boxed Warning for tacrolimus?

The FDA requires a Boxed Warning noting that prolonged use of topical calcineurin inhibitors (tacrolimus, pimecrolimus) has been associated with rare reports of lymphoma and skin cancer. This product should be used for the minimum duration needed and is not recommended for immunocompromised patients. However, causality has not been definitively established in published data.

Why is clindamycin at 2% rather than 1%?

The prescriber has customized this formulation with a higher clindamycin concentration appropriate for this patient's specific clinical picture, which may include more resistant bacterial colonization or a more inflammatory phenotype. Dosing decisions reflect clinical judgment.

Is this product FDA-approved?

No. This is a 503A compounded preparation from Genesis Compounding, specifically prepared for a named patient based on a prescriber's order. It is not an FDA-approved drug product at these exact ingredient concentrations.

How long before I notice improvement?

Anti-inflammatory effects of tacrolimus may begin within days to weeks; meaningful improvement in inflammatory papules and pustules typically requires 4–8 weeks of consistent use. Niacinamide effects on barrier and redness may be gradual over several weeks.